Targeted Therapy Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Targeted Therapy Market Size By 2025?
The market valuation for targeted therapies has experienced robust expansion over the preceding years, projected to ascend from $103.84 billion in 2024 to $109.99 billion across 2025, reflecting a compound annual growth rate of 5.9%. This historical upward trajectory is fundamentally linked to progress in molecular biology, the rising prevalence of cancer, the broader adoption of individualized medical treatments, and favorable endorsements and regulatory frameworks from the FDA.

How Big Is the Targeted Therapy Market Size Expected to Grow by 2029?
Anticipated within the coming years is substantial expansion for the targeted therapy sector, projected to reach a valuation of $146.89 billion by 2029, powered by a compound annual growth rate stability of 7.5%; this escalating trajectory is fueled by advancements in cancer research, an elevated need for personalized medical approaches, the advent of immunotherapy treatments, increased capital outlay into biopharmaceutical development, and greater patient consciousness and representation. Key developments shaping this era include the incorporation of sophisticated artificial intelligence in identifying new drugs, greater patient participation and influence in determining therapeutic courses, broader utilization of complementary diagnostic tools, governmental streamlining for quicker market entry permissions, alongside heightened financial backing directed towards biotech and pharmaceutical firms.

View the full report here:
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Which Key Market Drivers Powering Targeted Therapy Market Expansion and Growth?
Accelerating incidences of cancer are widely anticipated to fuel the expansion of the targeted therapy sector in the future. Cancer describes a group of illnesses characterized by the unauthorized spread of abnormal cells into nearby tissues alongside their unconstrained multiplication. Targeted therapy functions by intercepting the specific messages that promote the proliferation of malignant cells or by instructing those cells to initiate programmed death. This modality utilizes pharmaceuticals designed to zero in exclusively on the proteins and genetic factors sustaining the cancerous cells' viability and advancement, thereby boosting its market requirement. As an illustration, data released in January 2024 by the American Cancer Society, a US non-profit dedicated to cancer advocacy, indicated that the projection for new cancer diagnoses reached 2,001,140, up from 1,958,310 in 2023, signifying a rise of 2.19%; consequently, this expanding cancer burden will serve as a catalyst for the targeted therapy market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9129&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Targeted Therapy Market?
Leading corporations engaged within the precision medicine arena are concentrating their efforts on innovating novel technological approaches to bolster their market standing; specifically, in the third month of 2022, the Swiss multinational pharmaceutical giant, Novartis AG, introduced Pluvicto, which subsequently received clearance from the US Food and Drug Administration (FDA). This treatment represents the inaugural FDA-sanctioned targeted radioligand therapy (RLT) specifically for appropriate individuals diagnosed with mCRPC, essentially merging a therapeutic radioactive element with a specific targeting agent (a particle containing radioactivity). This form of focused cancer treatment works by having the Pluvicto attach itself to designated cells circulating in the bloodstream, such as those prostate cancer cells expressing the PSMA transmembrane protein; upon successful linkage, the energy emitted by the radioisotope damages these targeted cells alongside adjacent cells in the vicinity, thereby curbing their ability to multiply and/or causing their demise.

What Are the Emerging Segments in the Targeted Therapy Market?
The targeted therapymarket covered in this report is segmented -

1) By Type: Small Molecule Medicines; Monoclonal Antibodies
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Breast Cancer; Colorectal Cancer; Leukemia; Lung Cancer; Lymphoma; Renal Cancer; Other Applications

Subsegments:
1) By Small Molecule Medicines: Tyrosine Kinase Inhibitors (TKIs); Proteasome Inhibitors; Phosphatidylinositol 3-Kinase (PI3K) Inhibitors; Other Small Molecule Therapies
2) By Monoclonal Antibodies: Immune Checkpoint Inhibitors; Antibody-Drug Conjugates (ADCs); Cytokine Blockers; Other Monoclonal Antibodies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9129&type=smp

Who Are the Global Leaders in the Targeted Therapy Market?
Major companies operating in the targeted therapy market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Genmab A/S, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Agilent Technologies Inc., Illumina Inc., Incyte Corporation, Sysmex Corporation, Exact Sciences Corporation, Seagen Inc., Exelixis Inc., Seattle Genetics Inc., Genentech Inc., Daiichi Sankyo Company Limited

Which are the Top Profitable Regional Markets for the Targeted Therapy Industry?
North America was the largest region in the targeted therapy market in 2024. The regions covered in the targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9129

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.